Bcl-2 family proteins are essential for platelet survival
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Platelets are relatively short-lived, anucleated cells that are essential for proper hemostasis. The regulation of platelet survival in the circulation remains poorly understood. The process of platelet activation and senescence in vivo is associated with processes similar to those observed during apoptosis in nucleated cells, including loss of mitochondrial membrane potential, caspase activation, phosphatidylserine (PS) externalization, and cell shrinkage. ABT-737, a potent antagonist of Bcl-2, Bcl-X(L), and Bcl-w, induces apoptosis in nucleated cells dependent on these proteins for survival. In vivo, ABT-737 induces a reduction of circulating platelets that is maintained during drug therapy, followed by recovery to normal levels within several days after treatment cessation. Whole body scintography utilizing ([111])Indium-labeled platelets in dogs shows that ABT-737-induced platelet clearance is primarily mediated by the liver. In vitro, ABT-737 treatment leads to activation of key apoptotic processes including cytochrome c release, caspase-3 activation, and PS externalization in isolated platelets. Despite these changes, ABT-737 is ineffective in promoting platelet activation as measured by granule release markers and platelet aggregation. Taken together, these data suggest that ABT-737 induces an apoptosis-like response in platelets that is distinct from platelet activation and results in enhanced clearance in vivo by the reticuloendothelial system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [6]
In the citing paper
“a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Zhang et al., 2007
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a small molecule antagonist of the prosurvival Bcl-2 family proteins Bcl-XL, Bcl-2, and Bcl-w that induces apoptosis in tumor cells in a mitochondria-dependent fashion.(18) Treatment of ABT-737 in dogs leads to a rapid, dosedependent decrease in circulating platelets that return to baseline within 72-h post…”
BackgroundSelf-citationA receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491 · cited 1×
“PS externalization on cells has also been shown to signal the specific engulfment of these unwanted cells by phagocytes leading to clearance from the circulation .(9,15,25) Finally, the fact that the enantiomer negative control does not activate the apoptotic cascade at equivalent concentrations supports the notion th…”
BackgroundThe biogenesis of platelets from megakaryocyte proplatelets
Patel, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26891 · Cited by 603 · cited 1×
“The similarities between platelet biogenesis from megakaryocytes and apoptosis include membrane blebbing, membrane condensation, DNA fragmentation, cell shrinkage, and ultimately the formation of apoptotic bodies.(5,6) The consequence of this apoptotic process is that each mature megakaryocyte fragments into thousands…”
BackgroundThe platelet release reaction: granules' constituents, secretion and functions
Rendu, F., & Brohard-Bohn, B. (2001) · Platelets · doi:10.1080/09537100120068170 · Cited by 599 · cited 4×
“Upon platelet activation, a series of granules are released that are essential for the full activation response.(21) To further investigate other direct effects of ABT-737 on platelet dynamics, isolated platelets were treated with ABT-737 and classical markers of granule release were monitored.”
BackgroundMethodInfluentialProgrammed cell death and Bcl-2 protection in the absence of a nucleus.
Jacobson, M. D., Burne, J. F., & Raff, M. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06459.x · Cited by 552 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundMartin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28753 · Cited by 372 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundWolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G. P., Salvesen, G. S., & Green, D. R. (1999) · Blood · doi:10.1182/blood.v94.5.1683 · Cited by 323
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242 · cited 1×
“The process of apoptosis can be viewed as a cascade of events initiating from the accumulation of a death signal(s), release of apoptotic factors from the mitochondria, activation of initiator/effector caspases, ultimately leading to cell death.(16) Our studies demonstrate that ABT-737 initiates the apoptotic cascade…”
BackgroundA Simple Nonradioisotope Technic for the Determination of Platelet Life-Span
Stuart, M. J., Murphy, S., & Oski, F. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197506192922502 · Cited by 242 · cited 1×
“released into the circulation, platelets rapidly age with a halflife of 4–5 days.(7,8) As platelets age, they lose their ability to function and are subsequently removed from circulation.”
BackgroundRole of platelets in thrombosis and hemostasis
Packham, M. A. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-043 · Cited by 215 · cited 2×
“Subsequent platelet activation, granule release, and aggregation are essential for the formation of a hemostatic plug that limits blood loss and stimulates repair.(2) There are several morphological changes associated with platelet activation that are reminiscent of nucleated cell apoptosis.”
Background
Cited by
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
“We recently reported that ABT-737 induces a rapid and reversible thrombocytopenia in animals resulting from inhibition of Bcl-2 family proteins and induction of apoptosis in circulating platelets without bone marrow toxicity (29).”
BackgroundSelf-citationFisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032
“Navitoclax, and could be repurposed as senolytics, but cause considerable toxicity including neutropenia and platelet deficiency [40,41].”
BackgroundProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Self-citationRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
“Megakaryocytes and reticulated platelets are less susceptible, and thus compensatory increased megakaryopoiesis and partial correction of the thrombocytopenia are observed in preclinical models during ongoing dosing.(23) The objectives of this study were to define the safety profile, dose-limiting toxicity (DLT), maxi…”
BackgroundThirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
BCL-2 family antagonists for cancer therapy
Lessene, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 621
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
“This is a mechanism-based toxicity induced by inhibition of Bcl-xL in circulating platelets,(13,18) which is required for platelet survival.(19,20) Here we describe a phase I dose-escalation study to evaluate the safety (with particular attention to platelet dynamics), pharmacokinetics, and preliminary efficacy of nav…”
BackgroundDiagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580
Rudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
“ical models was a dose-dependent rapid thrombocytopenia, an on-target effect due to inhibition of Bcl-xL in platelets (15, 16).”
BackgroundLeverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Self-citationThe BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Cellular Mechanisms Underlying the Formation of Circulating Microparticles
Morel, O., Jesel, L., Freyssinet, J.-M., & Toti, F. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.200956 · Cited by 526
Getting to the Outer Leaflet: Physiology of Phosphatidylserine Exposure at the Plasma Membrane
Bevers, E. M., & Williamson, P. L. (2016) · Physiological Reviews · doi:10.1152/physrev.00020.2015 · Cited by 447
“Apoptosis regulatory proteins from the Bcl-2 protein family and effector caspases are present in platelets (328), and a gradual change in the balance between the anti-apoptotic Bcl-XL and pro-apoptotic Bax/ Bak leads to the onset of apoptosis and the clearance of senescent platelets (174).”
BackgroundLeverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Self-citationStructure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381
Cell Death in the Origin and Treatment of Cancer
Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 370
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Vogler, M., Dinsdale, D., Dyer, M. J. S., & Cohen, G. M. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.137 · Cited by 357
Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351
Anti-apoptotic BCL-2 family members in development
Opferman, J. T., & Kothari, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.170 · Cited by 347
“This initial observation spurred interrogation into how ABT-737 and its orally bioavailable derivative ABT-263 (navitoclax) induce platelet death by inhibiting BCL-XL function and triggering a BAK-dependent apoptosis in mature platelets.(79,80) Coincidentally, a genome wide N-ethyl-N-nitrosourea mouse screen identifie…”
BackgroundThe manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Grozovsky, R., Begonja, A. J., Liu, K., Visner, G., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2015) · Nature Medicine · doi:10.1038/nm.3770 · Cited by 336
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function
Schoenwaelder, S. M., Yuan, Y., Josefsson, E. C., White, M. J., Yao, Y., Mason, K. D., O'Reilly, L. A., Henley, K. J., Ono, A., Hsiao, S., et al. (2009) · Blood · doi:10.1182/blood-2009-01-200345 · Cited by 313
Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity
Tao, Z.-F., Hasvold, L., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 309
Self-citationPunnoose, E. A., Leverson, J. D., Peale, F., Boghaert, E. R., Belmont, L. D., Tan, N., Young, A., Mitten, M., Ingalla, E., Darbonne, W. C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0730 · Cited by 305
“Although navitoclax has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL), thrombocytopenia resulting from BCL-XL inhibition limited its dosing (20, 21).”
BackgroundABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 281
“Preclinical studies of ABT-737 also revealed decreased platelet survival [61].”
BackgroundPeirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., et al. (2014) · Blood · doi:10.1182/blood-2014-05-574566 · Cited by 264
Apoptosis and oncogenesis: give and take in the BCL-2 family
Llambi, F., & Green, D. R. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.12.001 · Cited by 262
“Exceptions include platelets [22,23], immature T lymphocytes [24 ] and mast cells [25].”
BackgroundTargeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Davids, M. S., & Letai, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.0981 · Cited by 261
“Two different laboratories have demonstrated that thrombocytopenia is an on-target toxicity resulting from the increasing dependence of platelets on BCL-XL for prevention of apoptosis as they age.(50,54) The data are strong enough that thrombocytopenia can be viewed as a pharmacodynamic marker of successful inhibition…”
BackgroundPayload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
“Inhibition of Bcl-xL has been associated with profound thrombocytopenia, justifying the search for highly specific Bcl-2 inhibitors such as venetoclax [160].”
BackgroundManaging thrombocytopenia associated with cancer chemotherapy.
Kuter, D. J. (2015) · PubMed · Cited by 290
Decoding and unlocking the BCL-2 dependency of cancer cells
Juin, P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3538 · Cited by 232
Mechanisms of platelet clearance and translation to improve platelet storage
Quach, M. E., Chen, W., & Li, R. (2018) · Blood · doi:10.1182/blood-2017-08-743229 · Cited by 223
Antibody-induced procoagulant platelets in severe COVID-19 infection
Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., Mehrländer, M., Hammer, S., Schulze, H., Bitzer, M., et al. (2021) · Blood · doi:10.1182/blood.2020008762 · Cited by 214
“5 (17-38) NT pro-BNP, ng/L 749 (385-3148) 1169 (239-4543) 537 (385-2324) .”
Apoptosis in the anucleate platelet
Leytin, V. (2012) · Blood Reviews · doi:10.1016/j.blre.2011.10.002 · Cited by 208
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 203
Self-citationVogler, M., Hamali, H. A., Sun, X.-M., Bampton, E. T. W., Dinsdale, D., Snowden, R. T., Dyer, M. J. S., Goodall, A. H., & Cohen, G. M. (2011) · Blood · doi:10.1182/blood-2011-03-344812 · Cited by 197
BH3-only proteins in apoptosis at a glance
Happo, L., Strasser, A., & Cory, S. (2012) · Journal of Cell Science · doi:10.1242/jcs.090514 · Cited by 193
“They are relatively well tolerated, despite the transient thrombocytopaenia caused primarily by inhibition of BCL-XL, which is the limiting factor for platelet survival (Mason et al., 2007; Zhang et al., 2007).”
BackgroundVandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 191
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
“BCL-XL is critical for platelet survival (26).”
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
Kuter, D. J. (2022) · Haematologica · doi:10.3324/haematol.2021.279512 · Cited by 184
Venetoclax for AML: changing the treatment paradigm
Pollyea, D. A., Amaya, M., Strati, P., & Konopleva, M. Y. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000937 · Cited by 174
Cellular senescence in the aging and diseased kidney
Valentijn, F. A., Falke, L. L., Nguyen, T. Q., & Goldschmeding, R. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0434-2 · Cited by 173
“For instance, navitoclax caused dosedependent thrombocytopenia, due to inhibition of BCL-X in platelets resulting in platelet apoptosis (Mason et al. 2007; Zhang et al. 2007; Wilson et al. 2010).”
BackgroundProcoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo
Reddy, E. C., & Rand, M. L. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00015 · Cited by 170
Procoagulant platelets: are they necrotic?
Jackson, S. P., & Schoenwaelder, S. M. (2010) · Blood · doi:10.1182/blood-2010-01-261669 · Cited by 169
Regulating billions of blood platelets: glycans and beyond
Grozovsky, R., Giannini, S., Falet, H., & Hoffmeister, K. M. (2015) · Blood · doi:10.1182/blood-2015-01-569129 · Cited by 169
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
Mohamad Anuar, N. N., Nor Hisam, N. S., Liew, S. L., & Ugusman, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.564108 · Cited by 168
Labi, V, Grespi, F., Baumgartner, F., & Villunger, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.37 · Cited by 165
Carrington, E. M., Zhan, Y., Brady, J. L., Zhang, J., Sutherland, R. M., Anstee, N. S., Schenk, R. L., Vikstrom, I. B., Delconte, R. B., Segal, D., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.30 · Cited by 182
“For example, platelets were found to be reliant on BCL-XL.(22,23) Naive T cells, naive B cells and plasmacytoid dendritic cells (pDC but not conventional DC, cDC) rely on BCL-2.”
BackgroundBCL-2 inhibition in AML: an unexpected bonus?
Konopleva, M., & Letai, A. (2018) · Blood · doi:10.1182/blood-2018-03-828269 · Cited by 164
“B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14;18) in follicular lymphoma >30 years ago.”
BackgroundBCL2: A promising cancer therapeutic target
Radha, G., & Raghavan, S. C. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.004 · Cited by 163
Kaefer, A., Yang, J., Noertersheuser, P., Mensing, S., Humerickhouse, R., Awni, W., & Xiong, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2530-9 · Cited by 161
“In contrast to the thrombocytopenia caused by traditional chemotherapies (which affect the production of platelet), navitoclax -induced thrombocytopenia is believed to be mechanism based and due to Bcl-Xl mediated senescence of circulating platelets [2, 9].”
BackgroundTurning back time with emerging rejuvenation strategies
Mahmoudi, S., Xu, L., & Brunet, A. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0206-0 · Cited by 161
Letai, A. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121933 · Cited by 161
“The BH3 domains of activator BH3-only proteins interact with BAX and BAK noncovalently to induce an allosteric change that facilitates their homodimerization (Brouwer et al. 2014, Lovell et al. 2008, Sarosiek et al. 2013, Suzuki et al. 2000, Zhang et al. 2016).”
BackgroundRoberts, A. W., & Huang, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.553 · Cited by 167
“BCLxL is a key survival factor for platelets(41) and, during the development of navitoclax, it was recognized that pharmacological inhibition of BCLxL would lead to apoptosis of platelets and acute thrombocytopenia.(42) In patients, highly reproducible doseproportional reductions in platelet counts were observed withi…”
BackgroundTargeting BCL2 for the Treatment of Lymphoid Malignancies
Anderson, M. A., Huang, D., & Roberts, A. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.008 · Cited by 149
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
Wang, L., Doherty, G. A., Judd, A. S., Tao, Z.-F., Hansen, T. M., Frey, R. R., Song, X., Bruncko, M., Kunzer, A. R., Wang, X., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00568 · Cited by 142
Self-citationTargeting BCL-2-like Proteins to Kill Cancer Cells
Cory, S., Roberts, A. W., Colman, P. M., & Adams, J. M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.001 · Cited by 161
BH3 mimetics to improve cancer therapy; mechanisms and examples
Zhang, L., Ming, L., & Yu, J. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.08.002 · Cited by 144
Bishton, M. J., Harrison, S. J., Martin, B. P., McLaughlin, N., James, C., Josefsson, E. C., Henley, K. J., Kile, B. T., Prince, H. M., & Johnstone, R. W. (2011) · Blood · doi:10.1182/blood-2010-11-318055 · Cited by 140
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139
Ryan, J., Montero, J., Rocco, J., & Letai, A. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 133
Understanding platelet generation from megakaryocytes: implications for in vitro–derived platelets
Sim, X., Poncz, M., Gadue, P. J., & French, D. L. (2016) · Blood · doi:10.1182/blood-2015-08-607929 · Cited by 145
“In megakaryocytes, the critical regulators are the Bcl-2 familymembers, Bcl-xL andMcl-1,33,34 whereas platelet lifespan is determined solely by Bcl-xL.31,35,36 Mice with a megakaryocyte-specific deletion of Bcl-xL were thrombocytopenic with an abundance of phosphatidylserine-positive microparticles in platelet-rich pl…”
BackgroundInfluentialvan Kruchten, R., Mattheij, N. J. A., Saunders, C. V., Feijge, M. A. H., Swieringa, F., Wolfs, J. L. N., Collins, P. W., Heemskerk, J. W. M., & Bevers, E. M. (2013) · Blood · doi:10.1182/blood-2012-09-454314 · Cited by 138
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 137
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M., & Letai, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 128
Self-citationBCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics
Soderquist, R. S., & Eastman, A. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0031 · Cited by 129
“Similarly, human platelets can be incubated with a BCLXL inhibitor such as ABT-737 ex vivo resulting in rapid cleavage of gelsolin, a marker of caspase activity (5).”
BackgroundProteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
“Unfortunately, the clinically effective dosage of ABT-263 is significantly limited by thrombocytopenia because platelets solely depend on Bcl-xL for survival [59].”
BackgroundTang, W. H., Stitham, J., Jin, Y., Liu, R., Lee, S. H., Du, J., Atteya, G. A., Gleim, S., Spollett, G. R., Martin, K. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005224 · Cited by 128
Cell death and the mitochondria: therapeutic targeting of the BCL ‐2 family‐driven pathway
Roy, M. J., Vom, A., Czabotar, P. E., & Lessène, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12431 · Cited by 138
“The origin of this phenomenon lies in the exquisite sensitivity of platelets to BCL-XL inhibition (Mason et al., 2007; Zhang et al., 2007), and, as such, these blood cells represent excellent biomarkers of on-target BCL-XL inhibition.”
BackgroundTetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors
Porter, J. R., Payne, A., de Candole, B., Ford, D., Hutchinson, B., Trevitt, G. P., Turner, J., Edwards, C., Watkins, C., Whitcombe, I. W. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.113 · Cited by 128
Targeting mitochondria for cancer therapy
Hockenbery, D. M. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20552 · Cited by 135
Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123
Apoptosis in megakaryocytes and platelets: the life and death of a lineage
McArthur, K., Chappaz, S., & Kile, B. T. (2017) · Blood · doi:10.1182/blood-2017-11-742684 · Cited by 135
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
Lock, R. B., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Maris, J. M., Keir, S. T., Wu, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21433 · Cited by 131
“following a single dose of ABT-737 and returned to baseline within 72 hr [31].”
BackgroundSelf-citationThe role of apoptosis in megakaryocytes and platelets
Kile, B. T. (2014) · British Journal of Haematology · doi:10.1111/bjh.12757 · Cited by 122
“Platelets stimulated to undergo apoptosis also expose PS (Zhang et al, 2007).”
BackgroundZeuner, A., Francescangeli, F., Contavalli, P., Zapparelli, G., Apuzzo, T., Eramo, A., Baiocchi, M., Angelis, M. L. D., Biffoni, M., Sette, G., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.105 · Cited by 117
“future targeted therapies specifically directed against Bcl-XL would have to face the problem of therapy-induced thrombocytopenia, as Bcl-XL has been shown to be essential for platelet survival.(30) One way to overcome this obstacle may be the design of novel Bcl-XL inhibitors with selective toxicity against tumor cel…”
BackgroundPhillips, D. C., Xiao, Y., Lam, L. T., Litvinovich, E., Roberts-Rapp, L. A., Souers, A. J., & Leverson, J. D. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.88 · Cited by 123
Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls
Owens, W. A., Walaszczyk, A., Spyridopoulos, I., Dookun, E., & Richardson, G. D. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111540 · Cited by 122
Mechanisms of resveratrol-induced platelet apoptosis
Lin, K., Hsiao, G., Shih, C.-M., Chou, D., & Sheu, J. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp139 · Cited by 108
“On the other hand, Zhang et al.(11) showed that the induction of platelet apoptosis enhances its clearance in vivo by the reticuloendothelial system.”
BackgroundInfluentialBurke, J. P., Bian, Z., Shaw, S., Zhao, B., Goodwin, C. M., Belmar, J., Browning, C. F., Vigil, D., Friberg, A., Camper, D. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501984f · Cited by 98
de Vos, S., Leonard, J. P., Friedberg, J. W., Zain, J., Dunleavy, K., Humerickhouse, R., Hayslip, J., Pesko, J., & Wilson, W. H. (2021) · Leukemia & Lymphoma · doi:10.1080/10428194.2020.1845332 · Cited by 94
“The DLT of navitoclax was thrombocytopenia [16,17] due to inhibition of BCL-XL, the key prosurvival protein sustaining circulating platelet survival [20,21].”
BackgroundMarkers of platelet apoptosis: methodology and applications
Gyulkhandanyan, A. V., Mutlu, A., Freedman, J. J., & Leytin, V. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0688-8 · Cited by 114
“Bak/Bax- and caspase-dependent, and -independent PS exposure [72] • in human and mouse platelets induced by ABT-737, CRP, CRP ? thrombin or A23187 • in normal Bak?”
BackgroundMethodInfluentialB Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Alam, M., Ali, S., Mohammad, T., Hasan, G. M., Yadav, D. K., & Hassan, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910442 · Cited by 108
Venetoclax: A new wave in hematooncology
Mihályová, J., Jelínek, T., Growková, K., Hrdinka, M., Šimíček, M., & Hájek, R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.002 · Cited by 110
The Essential Role of Evasion from Cell Death in Cancer
Kelly, G. L., & Strasser, A. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00002-7 · Cited by 112
“Cytokine deprivation has also been reported to activate Bim’s pro-apoptotic activity post-translationally as a consequence of loss of ERK mediated phosphorylation, which is thought to target Bim for ubiquitination and proteasomal degradation (reviewed in (Balmanno and Cook, 2009)) and to diminish its ability to bind a…”
BackgroundInfluentialRegulation of platelet lifespan by apoptosis
Lebois, M., & Josefsson, E. C. (2016) · Platelets · doi:10.3109/09537104.2016.1161739 · Cited by 108
“Despite its presence in platelets, the pro-survival guardian Bcl-w [21, 38] (Table I) is unlikely to play a major role in regulating platelet”
InfluentialRegulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
Haselager, M., Thijssen, R., West, C., Young, L., Van Kampen, R., Willmore, E., Mackay, S., Kater, A., & Eldering, E. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00692-w · Cited by 93
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
Klánová, M., & Klener, P. (2020) · Cancers · doi:10.3390/cancers12040938 · Cited by 105
“Thrombocytopenia was caused by inhibition of BCL-XL in platelets, that was shown to be dependent on BCL-XL for survival [90,91].”
BackgroundKhaw, S. L., Mérino, D., Anderson, M. A., Glaser, S. P., Bouillet, P., Roberts, A. W., & Huang, D. C. S. (2014) · Leukemia · doi:10.1038/leu.2014.1 · Cited by 100
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X. K., He, X., Lu, W., & Zhao, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584974 · Cited by 100
BCL-2 is dispensable for thrombopoiesis and platelet survival
Debrincat, M. A., Pleines, I., Lebois, M., Lane, R. M., Holmes, M. L., Corbin, J., Vandenberg, C. J., Alexander, W. S., Ng, A. P., Strasser, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.97 · Cited by 92
Vogler, M., Walter, H. S., & Dyer, M. J. S. (2017) · British Journal of Haematology · doi:10.1111/bjh.14684 · Cited by 99
“Platelet production however, is spared and younger platelets are less susceptible due to higher levels of expression of BCL-XL protein (Zhang et al, 2007).”
BackgroundPlatelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways
Josefsson, E. C., Burnett, D. L., Lebois, M., Debrincat, M. A., White, M. J., Henley, K. J., Lane, R. M., Moujalled, D., Preston, S., O’Reilly, L. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4455 · Cited by 97
Vela, L., & Marzo, I. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.014 · Cited by 102
Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival
Debrincat, M. A., Josefsson, E. C., James, C., Henley, K. J., Ellis, S., Lebois, M., Betterman, K. L., Lane, R. M., Rogers, K. L., White, M. J., et al. (2012) · Blood · doi:10.1182/blood-2011-12-398834 · Cited by 83
Kuroda, J., Kimura, S. H., Andreeff, M., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., Tanaka, R., Murotani, Y., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06899.x · Cited by 87
“The 5-day interval was established to permit platelet recovery (Mason et al, 2007; Zhang et al, 2007).”
Method
Metadata
- Authors
- Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., Preusser, L. C., Reinhart, G. A., Smith, M. L., Rosenberg, S. H., Elmore, S. W., & Tse, C.
- Affiliations
- Abbott (United States) (US)
- Corresponding author
- Elmore, S W
- Tse, C
- Venue
- Cell Death & Differentiation
- Published
- 2007-01-05
- Volume
- 14
- Issue
- 5
- Pages
- 943-951
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1976197588
- Cited by
- 427
- References
- 32
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 20 · 2022: 28 · 2021: 38 · 2020: 31 · 2019: 15 · 2018: 24 · 2017: 27 · 2016: 27 · 2015: 23 · 2014: 27 · 2013: 26 · 2012: 21
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet survival, Bcl-2 family proteins, ABT-737, platelet clearance, caspase-3 activation, cytochrome c release, phosphatidylserine exposure, mitochondrial membrane potential, reticuloendothelial system, hepatic clearance, platelet activation, hemostasis
- MeSH terms
- Animals, Biphenyl Compounds, Blood Platelets, Cell Separation, Cell Survival, Cytoplasmic Granules, Dogs, Dose-Response Relationship, Drug, Exocytosis, Flow Cytometry, Humans, Liver, Male, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Aggregation, Platelet Count, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.